Immunicum: Entering into a clinical collaboration with Merck KGaA / Pfizer
Research Note
2018-11-16
09:53
Today’s announcement of a clinical trial collaboration with Merck KGaA / Pfizer does not include any payments to Immunicum as far as we know, but we consider the agreement provides important external validation of ilixadencel. Another upside is the possibility of improved access to patients, as the agreement will probably get Immunicum more interest to run parts of the Iliad study in Europe.
KP
Klas Palin
Disclosures and disclaimers